Tumor lysis syndrome differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) |
|||
(7 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Tumor_lysis_syndrome]] | |||
{{CMG}} {{AE}} {{MJK}} | {{CMG}} {{AE}} {{MJK}} | ||
==Overview== | ==Overview== | ||
Tumor lysis syndrome must be differentiated from other diseases that cause [[hyperuricemia]], [[hyperkalemia]], and [[hyperphosphatemia]], such as [[acute kidney injury]]. | Tumor lysis syndrome must be differentiated from other diseases that cause [[hyperuricemia]], [[hyperkalemia]], and [[hyperphosphatemia]], such as [[acute kidney injury]]. The common conditions are hereditary hyperuricemia, [[Insulin resistance]], [[Hypertension]], [[Obesity]], [[Gout]], [[Alcoholism]] and [[renal insufficiency]]. Patients taking [[ACE inhibitor]], [[Non-steroidal anti-inflammatory drugs|NSAIDs]] and [[Antibiotics]] such as [[trimethoprim]] are more prone to hyperkalemia. [[Hyperphosphatemia]] is usually seen in [[Acute kidney injury]], [[Hypoparathyroidism]], [[Hypervitaminosis D|vitamin D]] supplementation and also in [[Sarcoidosis|sarcoidos]]. | ||
==Differentiating tumor lysis syndrome from other Diseases== | ==Differentiating tumor lysis syndrome from other Diseases== | ||
Tumor lysis syndrome must be differentiated from other diseases that cause electrolytes disturbance.<ref name="pmid24359983">{{cite journal| author=Wilson FP, Berns JS| title=Tumor lysis syndrome: new challenges and recent advances. | journal=Adv Chronic Kidney Dis | year= 2014 | volume= 21 | issue= 1 | pages= 18-26 | pmid=24359983 | doi=10.1053/j.ackd.2013.07.001 | pmc=PMC4017246 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24359983 }} </ref> | Tumor lysis syndrome must be differentiated from other diseases that cause electrolytes disturbance.<ref name="pmid24359983">{{cite journal| author=Wilson FP, Berns JS| title=Tumor lysis syndrome: new challenges and recent advances. | journal=Adv Chronic Kidney Dis | year= 2014 | volume= 21 | issue= 1 | pages= 18-26 | pmid=24359983 | doi=10.1053/j.ackd.2013.07.001 | pmc=PMC4017246 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24359983 }} </ref> | ||
Line 27: | Line 28: | ||
::*[[Angiotensin II receptor antagonist|angiotensin receptor blockers]] | ::*[[Angiotensin II receptor antagonist|angiotensin receptor blockers]] | ||
::*Potassium-sparing [[diuretic]]s such as[[amiloride]] and [[spironolactone]] | ::*Potassium-sparing [[diuretic]]s such as[[amiloride]] and [[spironolactone]] | ||
::*[[Non-steroidal anti-inflammatory drugs|NSAIDs]] such as [[ibuprofen]] and[[naproxen]] | ::*[[Non-steroidal anti-inflammatory drugs|NSAIDs]] such as [[ibuprofen]] and [[naproxen]] | ||
::*[[Ciclosporin]] | ::*[[Ciclosporin]] | ||
::*[[Tacrolimus]] | ::*[[Tacrolimus]] | ||
::*[[Antibiotics]] such as [[trimethoprim]] | ::*[[Antibiotics]] such as [[trimethoprim]] | ||
::*[[Antiparasitic]] drugs such as [[pentamidine]] | ::*[[Antiparasitic]] drugs such as [[pentamidine]] | ||
:*[[Mineralocorticoid]] deficiency or resistance | :*[[Mineralocorticoid]] deficiency or resistance: | ||
::*[[Addison's disease]] | ::*[[Addison's disease]] | ||
::*[[Hypoaldosteronism|Aldosterone deficiency]] | ::*[[Hypoaldosteronism|Aldosterone deficiency]] | ||
Line 60: | Line 61: | ||
::*[[Respiratory acidosis]] | ::*[[Respiratory acidosis]] | ||
<ref name=" | === Differentiating tumor lysis syndrome based on hyperkalemia: === | ||
{| align="center" | |||
|- | |||
| | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | |||
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Organ system | |||
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Conditions | |||
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Distinguishing features | |||
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Additional findings | |||
|- | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Symptoms | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Signs | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Labs | |||
|- | |||
| rowspan="2" style="background:#DCDCDC;" align="center" |'''Tissue break down''' | |||
| style="background:#DCDCDC;" align="center" |'''[[Tumor lysis syndrome]]<ref name="pmid18509186">{{cite journal |vauthors=Coiffier B, Altman A, Pui CH, Younes A, Cairo MS |title=Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review |journal=J. Clin. Oncol. |volume=26 |issue=16 |pages=2767–78 |year=2008 |pmid=18509186 |doi=10.1200/JCO.2007.15.0177 |url=}}</ref>''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Fever]], [[weight loss]], symptoms related to underlying malignancy | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Altered mental status]], [[lymphadenopathy]], [[muscle weakness]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperkalemia]], [[hyperphosphatemia]], [[hypocalcemia]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |History of underlying malignancy | |||
|- | |||
| style="background:#DCDCDC;" align="center" |'''[[Rhabdomyolysis]]<ref name="pmid6282181">{{cite journal |vauthors=Knochel JP |title=Rhabdomyolysis and myoglobinuria |journal=Annu. Rev. Med. |volume=33 |issue= |pages=435–43 |year=1982 |pmid=6282181 |doi=10.1146/annurev.me.33.020182.002251 |url=}}</ref>''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Myalgia]], [[fatigue]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Altered mental status]], [[hypotension]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperkalemia]], increased muscle enzymes (CK, aldolase) | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |History of [[seizure]], [[drug overdose]], or [[trauma]] | |||
|- | |||
| rowspan="3" style="background:#DCDCDC;" align="center" |'''Renal''' | |||
| style="background:#DCDCDC;" align="center" |'''[[Acute kidney injury]]<ref name="pmid17331245">{{cite journal |vauthors=Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A |title=Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury |journal=Crit Care |volume=11 |issue=2 |pages=R31 |year=2007 |pmid=17331245 |pmc=2206446 |doi=10.1186/cc5713 |url=}}</ref>''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Nausea]], [[vomiting]], decreased [[urine output]], [[fatigue]], [[dyspnea]], [[edema]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Tremor]], [[confusion]], [[edema]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperkalemia]], [[Azotemia|increased BUN and Cr]], [[metabolic acidosis]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Recently developed symptoms | |||
|- | |||
| style="background:#DCDCDC;" align="center" |'''[[Chronic kidney disease]]<ref name="pmid12138150">{{cite journal |vauthors=Rodríguez Soriano J |title=Renal tubular acidosis: the clinical entity |journal=J. Am. Soc. Nephrol. |volume=13 |issue=8 |pages=2160–70 |year=2002 |pmid=12138150 |doi= |url=}}</ref>''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Nausea]], [[vomiting]], decreased [[urine output]], [[fatigue]], [[dyspnea]], [[edema]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Tremor]], [[confusion]], [[edema]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperkalemia]], [[Azotemia|increased BUN and Cr]], [[metabolic acidosis]], [[hypocalcemia]], [[hyperphosphatemia]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Chronic underlying disease ([[Diabetes mellitus|DM]], [[Hypertension|HTN]]), duration of symptoms ≥ 3 months | |||
|- | |||
| style="background:#DCDCDC;" align="center" |'''[[Renal tubular acidosis|Renal tubular acidosis type-4]]<ref name="pmid15262664">{{cite journal |vauthors=Hsu CY, Vittinghoff E, Lin F, Shlipak MG |title=The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency |journal=Ann. Intern. Med. |volume=141 |issue=2 |pages=95–101 |year=2004 |pmid=15262664 |doi= |url=}}</ref>''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Usually asyptomatic | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Signs of underlying disease | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperkalemia]], normal anion gap metabolic acidosis, urine PH< 5.5 | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |History of [[diabetes mellitus]] | |||
|- | |||
| rowspan="4" style="background:#DCDCDC;" align="center" |'''Endocrine''' | |||
| style="background:#DCDCDC;" align="center" |'''[[Diabetic ketoacidosis|DKA]]<ref name="pmid19564476">{{cite journal |vauthors=Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN |title=Hyperglycemic crises in adult patients with diabetes |journal=Diabetes Care |volume=32 |issue=7 |pages=1335–43 |year=2009 |pmid=19564476 |pmc=2699725 |doi=10.2337/dc09-9032 |url=}}</ref>''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Change in mental status]], [[abdominal pain]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Decreased skin turgor, dry oral mucosa, [[tachycardia]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperglycemia]], increased anion gap [[metabolic acidosis]], [[ketonemia]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Rapidly developing [[polyuria]], [[polydipsia]], and [[weight loss]] | |||
|- | |||
| style="background:#DCDCDC;" align="center" |'''[[Hyperosmolar hyperglycemic state|HHS]]<ref name="pmid5013637">{{cite journal |vauthors=Arieff AI, Carroll HJ |title=Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases |journal=Medicine (Baltimore) |volume=51 |issue=2 |pages=73–94 |year=1972 |pmid=5013637 |doi= |url=}}</ref>''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Change in mental status]], [[abdominal pain]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Decreased skin turgor, dry oral mucosa, [[tachycardia]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Severe [[hyperglycemia]], normal anion gap, increased serum osmolality | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Polyuria]], [[polydipsia]], and [[weight loss]] develop more insidious | |||
|- | |||
| style="background:#DCDCDC;" align="center" |'''[[Congenital adrenal hyperplasia]] (CAH)<ref name="pmid20823466">{{cite journal |vauthors=Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC |title=Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4133–60 |year=2010 |pmid=20823466 |pmc=2936060 |doi=10.1210/jc.2009-2631 |url=}}</ref><ref name="pmid19955259">{{cite journal |vauthors=Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, Ventz M, Quinkler M, Allolio B |title=Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies |journal=Eur. J. Endocrinol. |volume=162 |issue=3 |pages=597–602 |year=2010 |pmid=19955259 |doi=10.1530/EJE-09-0884 |url=}}</ref>''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Poor feeding]], [[failure to thrive]], [[precocious puberty]], short statue, [[hirsutism]], [[weight loss]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Ambiguous genitalia]], [[hypotension]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperkalemia]], increased [[17-alpha-hydroxyprogesterone|17 hydroxyprogestrone]], [[hyponatremia]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Salt wasting | |||
|- | |||
| style="background:#DCDCDC;" align="center" |[[Addison's disease|'''Addison's disease''']] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Skin [[hyperpigmentation]], [[fatigue]], salt craving, [[nausea and vomiting]], [[amenorrhea]], [[depression]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperpigmentation]], [[hypotension]], pubic and axillary hair loss | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperkalemia]], decreased serum cortisol level | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Diagnosis by cosyntropin test | |||
|} | |||
|} | |||
==References== | ==References== | ||
Line 67: | Line 140: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] |
Latest revision as of 13:33, 1 July 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Tumor lysis syndrome must be differentiated from other diseases that cause hyperuricemia, hyperkalemia, and hyperphosphatemia, such as acute kidney injury. The common conditions are hereditary hyperuricemia, Insulin resistance, Hypertension, Obesity, Gout, Alcoholism and renal insufficiency. Patients taking ACE inhibitor, NSAIDs and Antibiotics such as trimethoprim are more prone to hyperkalemia. Hyperphosphatemia is usually seen in Acute kidney injury, Hypoparathyroidism, vitamin D supplementation and also in sarcoidos.
Differentiating tumor lysis syndrome from other Diseases
Tumor lysis syndrome must be differentiated from other diseases that cause electrolytes disturbance.[1]
- Hereditary hyperuricemia
- Insulin resistance
- Hypertension
- Obesity
- Gout
- Alcoholism
- Renal insufficiency
- Medications:
- Renal insufficiency
- Medications
- ACE inhibitor
- angiotensin receptor blockers
- Potassium-sparing diuretics such asamiloride and spironolactone
- NSAIDs such as ibuprofen and naproxen
- Ciclosporin
- Tacrolimus
- Antibiotics such as trimethoprim
- Antiparasitic drugs such as pentamidine
- Mineralocorticoid deficiency or resistance:
- Addison's disease
- Aldosterone deficiency
- Some forms of congenital adrenal hyperplasia
- Type IV renal tubular acidosis
- Gordon's syndrome (pseudohypoaldosteronism type II)
- Acute kidney injury
- Hypoparathyroidism
- Vitamin D
- vitamin A intoxication
- Sarcoidosis
- Immobilization
- Osteolytic metastases
- Milk-alkali syndrome
- Severe hypermagnesemia or hypomagnesemia
- Pseudohypoparathyroidism
- Acromegaly
- Extensive cellular injury or necrosis:
- Crush injury
- Rhabdomyolysis
- Hyperthermia
- Fulminant hepatitis
- Severe hemolytic anemia
- Transcellular phosphate shifts:
Differentiating tumor lysis syndrome based on hyperkalemia:
References
- ↑ Wilson FP, Berns JS (2014). "Tumor lysis syndrome: new challenges and recent advances". Adv Chronic Kidney Dis. 21 (1): 18–26. doi:10.1053/j.ackd.2013.07.001. PMC 4017246. PMID 24359983.
- ↑ 2.0 2.1 2.2 Wikipedia.https://en.wikipedia.org/wiki/Hyperuricemia
- ↑ Coiffier B, Altman A, Pui CH, Younes A, Cairo MS (2008). "Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review". J. Clin. Oncol. 26 (16): 2767–78. doi:10.1200/JCO.2007.15.0177. PMID 18509186.
- ↑ Knochel JP (1982). "Rhabdomyolysis and myoglobinuria". Annu. Rev. Med. 33: 435–43. doi:10.1146/annurev.me.33.020182.002251. PMID 6282181.
- ↑ Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A (2007). "Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury". Crit Care. 11 (2): R31. doi:10.1186/cc5713. PMC 2206446. PMID 17331245.
- ↑ Rodríguez Soriano J (2002). "Renal tubular acidosis: the clinical entity". J. Am. Soc. Nephrol. 13 (8): 2160–70. PMID 12138150.
- ↑ Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004). "The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency". Ann. Intern. Med. 141 (2): 95–101. PMID 15262664.
- ↑ Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009). "Hyperglycemic crises in adult patients with diabetes". Diabetes Care. 32 (7): 1335–43. doi:10.2337/dc09-9032. PMC 2699725. PMID 19564476.
- ↑ Arieff AI, Carroll HJ (1972). "Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases". Medicine (Baltimore). 51 (2): 73–94. PMID 5013637.
- ↑ Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC (2010). "Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline". J. Clin. Endocrinol. Metab. 95 (9): 4133–60. doi:10.1210/jc.2009-2631. PMC 2936060. PMID 20823466.
- ↑ Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, Ventz M, Quinkler M, Allolio B (2010). "Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies". Eur. J. Endocrinol. 162 (3): 597–602. doi:10.1530/EJE-09-0884. PMID 19955259.